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ized by rapidly progressive vascular myointimal
hyperplasia leading to either diffuse, concentric,
homogenous lesions spreading uniformly along the
length of arteries or focal stenoses.2 Coronary angiog-
raphy is the most widely used technique for detection
of CAV because it provides clinically useful informa-
tion regarding the prevalence and severity of coronary
artery lesions.
Although CAV has been the subject of intense study,
the relationship between the occurrence and severity of
this disease and cytokines is still unknown. The pro-
duction of growth factors in the allograft coronary
lesions has been demonstrated by means of in situ
hybridization techniques.3 Inflammatory cells, includ-
ing macrophages, as well as platelets and endothelial
cells play direct and indirect roles in cardiac allograft
injury and repair.4 Evidence is accumulating that the
cytokine network is involved in generating and main-
taining graft atherosclerosis.5
Cardiac allograft vasculopathy (CAV) contributessignificantly to long-term morbidity in heart trans-
plant recipients, and it is the commonest cause of
death and retransplantation after 2 years.1 CAV is an
accelerated form of coronary artery disease character-
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TRANSFORMING GROWTH FACTOR β IN RELATION TO CARDIAC ALLOGRAFT VASCULOPATHY
AFTER HEART TRANSPLANTATION
The contribution of transforming growth factor
(TGF-β) to the development of coronary artery disease
in heart transplants is undefined. Increased expression
of TGF-β1 in human vascular stenotic lesions has been
previously reported.6 In solid organ transplantation,
TGF-β has been implicated in the development of
glomerulosclerosis mediated by its dual action of
increasing deposition and decreasing degradation of
the extracellular matrix.7
In the present study we have examined the involve-
ment of TGF-β, in association with histologic, clinical,
and genetic factors, in the generation of angiographical-
ly proven CAV after orthotopic heart transplantation. 
Methods
This retrospective study analyzed the risk factors for devel-
opment of coronary artery disease in heart transplant recipi-
ents. The study involves immunohistochemical assessment of
the recipient’s endomyocardial biopsy tissue in the absence
of cellular rejection. As the majority of our recipients had cel-
lular rejection during the first 18 months after transplantation,
we restricted our analysis to recipients who survived at least
24 months after their operation.
Patients. Between 1987 and 1996, 208 orthotopic heart
transplantations were performed at our center. A total of 175
orthotopic heart transplant recipients survived more than 2
years, and they were considered for this study. The age at
transplantation was 46 ± 10 years and 81% were men.
Recipients having heart retransplantation or those who sur-
vived for less than 24 months after the operation were exclud-
ed from this study. The standard technique8 was performed in
99 recipients and the bicaval9 procedure in 76 recipients.
Follow-up was complete to December 1998 or to the time of
death and ranged from 39 to 135 months. 
Endomyocardial biopsies. Surveillance endomyocardial
biopsies were performed through a percutaneous right inter-
nal jugular approach. At least 4 to 5 biopsies were performed
during each biopsy session. The biopsy sessions were per-
formed on a scheduled basis: weekly for the first month,
every 2 weeks for the next 2 months, monthly until 6 months,
then at 9, 12, and 18 months after transplantation, and yearly
thereafter. In the event of clinical suspicion of rejection in the
interim, further biopsies were performed as indicated. Biopsy
specimens were evaluated for rejection by means of
International Society for Heart and Lung Transplantation
(ISHLT) criteria.10
Triple-drug immunosuppression with cyclosporine (INN:
ciclosporin), azathioprine, and steroid therapy was used in all
patients in addition to an initial 3-day application of cytolyt-
ic induction therapy (rabbit-antithymocyte globulin, 2
mg/kg). Acute rejection was treated with bolus methylpred-
nisolone (500 mg daily for 3 days) and follow-up endomyo-
cardial biopsy was performed 1 to 2 weeks later to assess out-
come of treatment. Treatment was given only when the
degree of rejection was 3A or more or when the patients were
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in a clinically compromised condition. For the purpose of this
study, a rejection episode was defined as the presence in at
least one biopsy specimen of ISHLT grade 2 rejection or
higher. Subsequent positive biopsy results were considered to
be the same rejection episode if not separated by a rejection-
free biopsy result. 
Coronary angiography and definition of graft athero-
sclerosis. Each patient underwent surveillance coronary
angiography starting 2 years after transplantation and repeat-
ed annually at the time of biopsy. 
Coronary angiograms were assessed by means of the pro-
tocol for angiographic assessment of coronary artery disease
in heart transplant recipients as described previously by the
Cardiac Transplant Research Database group.11 The degree
of CAV was assessed in all the main coronary vessels and
their primary branches. A primary coronary vessel was
defined as the proximal two thirds of the left anterior
descending artery, left circumflex, or a dominant or co-dom-
inant right coronary artery. A branch vessel was defined as
the distal one third of the left anterior descending artery, its
diagonal branches, obtuse marginal branches, intermediate
artery, and/or a nondominant right coronary artery. Scoring of
CAV was based on involvement of the left main stem coro-
nary artery, primary, and branch vessel stenoses. The disease
score is shown in Table I. The final score was calculated for
each patient and was assessed as no CAV (score = 0), mini-
mal CAV (score 1-3), mild CAV (score 4-7), moderate CAV
(score 8-10), and severe CAV (score ≥ 10). 
Since donors were young (36 ± 10 years) and recipients
receiving an old donor heart (>50 years) had a coronary
angiogram soon after transplantation, we did not assume that
early CAV represented pre-existing donor disease. 
Histologic examination and immunohistochemistry.
Only endomyocardial biopsy specimens taken at least 2 years
after transplantation were selected for immunohistochemical
assessment. A total of 4721 endomyocardial biopsy speci-
mens, taken mainly from the interventricular septum obtained
during baseline follow-up and at the time of angiographic
studies, were graded according to the ISHLT classification
system.10 So that the immediate effects of current rejection
could be avoided, specimens taken from recipients in whom
the previous biopsy result showed evidence of cellular rejec-
tion (any grade other than 0) were excluded from immuno-
histochemical staining for the purposes of this study (n = 863
biopsy specimens). Also, specimens taken from patients
requiring additional immunosuppression for any reason were
also excluded (n = 199 biopsy specimens). The rest of the
endomyocardial biopsy specimens (n = 3659) were included
for immunohistochemical staining.
Paraffin-embedded sections fixed in 4% formaldehyde
were dewaxed and rehydated with limonene (Citroclear; HD
Supplies, Aylesbury, Bucks, United Kingdom), alcohol, and
water for 10 minutes and then treated with 10% proteinase K
(Dako, Bucks, United Kingdom) in Tris-buffered saline
(TBS) solution. Nonspecific binding was blocked with 10%
normal swine serum (Chemicon International Ltd, Harrow,
United Kingdom). Mouse anti-human TGF-β antibody was
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diluted 1:10 in TBS and applied to 3 of the 4 sections on each
slide while the remaining section received only TBS without
antibodies. The slides were incubated for 1 hour, then washed
and stained with peroxidase-conjugated anti-mouse
immunoglobulin G at 1:1000 dilution (Sigma Immuno-
chemical, St Louis, Mo) for 2 hours, after which slides were
transferred to fresh diaminobenzidine. The slides were coun-
terstained with Meyer’s haemalum (Sigma Immuno-
chemical), dehydrated, and mounted with dibutyl polystyrene
xylene (DPX). To confirm the staining specificity, we per-
formed blocking studies with recombinant TGF-β (R&D
Systems, Abingdon, Oxon, United Kingdom) to inhibit bind-
ing of anti–TGF-β antibodies. Macrophages were identified
in sections by means of an indirect immunoperoxidase tech-
nique with a mouse monoclonal antibody, CD68 (reagent
PGM-1, Dako). 
Immunohistochemistry quantification
TGF-β staining assessment. We used the same immunohis-
tochemical staining score that was previously described by
our laboratory for assessment of TGF staining in human allo-
grafts.12 The scoring for TGF-β and CD+68 scoring took into
account 3 factors:
1. The absolute number of TGF-β staining cells and CD68-
positive cells per high-power field (0.202 mm2) was quanti-
fied with an eyepiece graticule. At least 40 fields were count-
ed with the use of a ×40 objective lens so that the percentage
standard deviation was less than 2% for at least 5 fields. The
fields covered the entire field of each biopsy and any biopsy
specimen without 40 separate fields was excluded. 
2. The percentage and number of positive cells (myocytes,
interstitium, or inflammatory cells) was also assessed by
quantifying the number of cellular infiltrates and expressing
them as a percentage of total number of infiltrating cells per
field at 4 × 40 objective. 
3. The intensity of positive cellular staining was evaluated
(Table II).
Fibrosis assessment. Fibrosis was assessed in sections
stained with hematoxylin and eosin. Slides were scanned
with a ×10 objective lens. Each successive field was individ-
ually assessed for severity (as a percentage) of interstitial
myocardial fibrosis (see Table II). After the entire section was
examined, the mean score of all the fields was taken as the
fibrosis score. Two independent blinded observers scored
each biopsy specimen. A similar score was achieved in 81%
of the biopsy specimens. Biopsy specimens with scoring dif-
ferences of more than 1 point (n = 703 biopsy specimens)
were reviewed to reach an agreement regarding the final
score of the slides. 
Each biopsy specimen consisted of 3 to 5 pieces. TGF
score was calculated for each separate piece and then added
together to calculate mean TGF-β for each single biopsy
specimen.
Development of TGF-β and CAV scoring systems for
each patient. Mean TGF-β and CAV scores were calculated
annually for each patient starting from 24 months after the
operation till the end point of this study (patient death or
December 1998). In total, 679 angiographic assessments
were performed for the entire study population (Table III).
Genotyping of TGF-β1 gene polymorphisms in trans-
plant recipients. Patients were genotyped for a biallelic
Table I. Categorization of CAV
CAV score for each vessel stenosis
Vessel stenosis LMS Primary vessel Branches
Normal 0 0 0
<50% 3 2 1
50%-70% 6 4 2
70%-90% 9 6 3
>90% 12 8 4
The lesions were scored according to their severity and vessel significance.
LMS, Left main stem coronary artery.
Table II. TGF-β scoring system
Histopathologic assessment Score
Positive TGF-β staining in cells
Yes 1









Positive TGF-β staining in fibrous tissue
Yes 1









Total maximum score 14
Table III. Number of angiographic and immunohisto-
chemistry assessments for the study population







The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 4, Part 1
Aziz et al 703
polymorphism in the TGF-β1 gene related to higher or lower
TGF-β production in vitro. The 2 alleles encode either argi-
nine at codon 25, associated with higher TGF-β production,
or proline, which is associated with lower TGF-β production.
DNA was extracted from whole blood and genotyped by
means of a polymerase chain reaction–based method.13
Data collection and statistical analysis. The mean follow-
up period for the study population was 68 ± 32 months after
heart transplantation. In addition to vasculopathy, the study
investigators collected vasculopathy score, TGF score, and 16
demographic and medical history variables believed to be rel-
evant to the development of CAV after heart transplantation.
Medical history variables were defined as patient report of a
previous diagnosis by a physician. All statistical analyses
were completed with SPSS software (Windows 7.5; SPSS,
Inc, Chicago, Ill). A univariate analysis was done that ana-
lyzed the possible relationship between CAV and the vari-
ables collected. Contingency table analyses for categorical
data and t tests or their nonparametric analog (Mann-Whitney
U test) for continuous variables were used. Some variables
required log transformations to achieve approximate normal-
ity or constancy or additivity of scale. Any variable that
achieved a P value of .10 or less in the univariate analysis was
included in the model. Multivariable analyses were per-
formed by means of the Cox proportional hazard model on
StatView J 4.11 software (Abacus Concepts, Inc, Berkeley,
Calif). Forward and backward stepwise procedures were used
to determine the combination of factors that were significant
in the development of CAV after heart transplantation. If vari-
ables could be used as continuous variables, continuous vari-
ables were used in multivariate analysis. The regression and
correlation analysis was used to compare the values of the
immunohistochemistry score, TGF score, and the prevalence
of rejection episodes. Adjusted correlation taking the time
interval into consideration was used to assess the relation
between TGF score and immunohistochemistry score during
the study. 
Results
Two years after transplantation (study beginning
and baseline assessment). Thirty-four angiograms
were performed within the first 18 months after trans-
plantation because of graft dysfunction in 4, old donor
age in 6, and symptoms of congestive heart failure in 24
cases. Minimal to mild coronary artery disease was
identified in the first year after heart transplantation in
only 3 recipients, and they have been excluded from
our analysis. 
After the analysis of the surveillance recipients’
angiograms at a 1-year interval after transplantation,
we could classify the recipients into 4 groups: 131
(76%) with normal-minimal coronary artery anatomy,
31 (16.5%) with mild graft CAV, 6 (3%) with moderate
CAV, and 8 (4.5%) with severe CAV. 
TGF-β was immunolocalized in the myocardium,
interstitium, blood vessels, macrophages, and in areas
of fibrosis (Fig 1). TGF-β was strongly expressed in the
endomyocardial biopsy specimen from patients with
moderate or severe CAV (95% confidence interval [CI]
= 7.8-9.3) in comparison with those with minimal or
mild CAV (95% CI = 2.9-4.2), P = .0002.
Correlation between CAV and TGF-β scoring dur-
ing the study period. During the study period (1987-
1998 or the patient’s death), both TGF-β score and coro-
nary artery disease score were assessed annually for each
surviving patient. The annual development of moderate-
severe CAV (coronary artery disease score > 7) was 3.9%
in our recipients. The number of repeated assessments for
the study population is shown in Table III.
Increased TGF-β positive staining preceded the
angiographic detection of CAV by 11 to 15 months.
Eighty-two percent of patients (n = 61 patients) who
had a TGF-β staining score of more than 7 at any point
of the study and normal angiograms at that time had
significant CAV develop within 12 months. 
Fig 1. TGF-β staining of the myocardial biopsy specimen. A,
Low staining score in a specimen showing no or minimal
CAV. B, Strong staining score in an example of severe CAV.
A
B
Progression of allograft coronary artery disease was
diagnosed in 76 patients with a TGF-β score of more
than 7 at an average of 12 months later. Progression
was evidenced by new angiographic abnormalities in
69 patients and worsening of pre-existing mild-mini-
mal coronary artery disease lesions in 7 patients. 
New angiographic abnormalities were observed in 6
patients with mild coronary artery disease, in 32 patients
with moderate disease, and in 31 patients with severe
disease. These new abnormalities consisted mainly of
new focal coronary artery disease (51 patients) and dif-
fuse coronary artery disease (18 patients). 
If the TGF-β staining score was more than 10, the
likelihood of progression to severe coronary artery dis-
ease within 12 months was 41% compared with 15%
when the TGF-β score was less. Progression of coro-
nary artery disease strongly correlated with a higher
TGF-β staining score in the endomyocardial biopsy
specimens obtained during the same period (r = 0.73, P
= .0007) (Fig 2).
Study end point. At the end of the study period
(1998 or patient death), the recipients were classified
into 4 groups according to their last angiographic
assessment; 48 (28%) with normal/minimal coronary
artery anatomy, 34 (19.5%) with mild graft CAV, 49
(28.5%) with moderate CAV, and 41 (24%) with severe
graft CAV. 
Higher TGF-β expression was sustained in patients
who had moderate or severe CAV (95% CI = 8.9-12.1)
compared with those who had minimal or mild CAV
changes (score > 7; 95% CI = 3.4-5.1), P = .0001.
Comparison of variables between recipients with mod-
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erate or severe CAV (n = 90) and those who did not
show relevant CAV changes (n = 82) are summarized in
Table IV.
Risk factors for CAV after transplantation and
survival. The TGF-β score at the study end point cor-
related with the number of rejection episodes that
occurred during the first 2 years after transplantation (r
= 0.69, P = .003) (Fig 3). Significant correlation has
been also found between the prevalence of rejection
episodes during the first 2 years after transplantation
and the long-term development of graft CAV (Fig 4).
Multivariable analysis identified the weight of each
variable in the development of coronary artery disease.
TGF-β score was the strongest determinant of disease
development. Other significant factors were homozy-
gous high TGF-β producer genotype, number of grade
2 or more rejection episodes, donor age, recipient his-
tory of ischemic heart disease before transplantation,
donor history of subarachnoid bleeding, and donor
male sex (Table V).
Thirty-six patients have died, and the cause of death
was reported to be moderate to severe graft atheroscle-
rosis in 21 recipients. Among 15 (71%) of 21 recipients
who died of graft CAV, the final TGF score was more
than 10. Multivariable analyses with the Cox propor-
tional hazards model disclosed that TGF score was a
single independent prognostic factors for survival in
our study population (95% CI 1.3-1.43 for each unit of
the TGF score).
Discussion 
Relevance of graft CAV after heart transplanta-
tion. CAV is the most common cause of morbidity and
mortality in patients surviving for more than 2 years
after transplantation,1,14 but the spectrum of lesions
varies considerably. Since CAV is usually asympto-
matic and sometimes develops and progresses rapidly,
identification of patients at high risk is important.
Insights into pathology. The pathogenesis of CAV is
poorly understood and is quite different from athero-
sclerosis in native coronary artery disease. Coronary
arterial involvement is usually diffuse with long seg-
ments of all levels of vessels affected in a relatively
uniform manner. It has been postulated that changes in
the allograft coronary circulation originate from an
interaction between immune and nonimmune factors
that lead to smooth muscle cellular infiltration and
accumulation of expanded neointima. Reape, Rayner,
and Manning15 have reported excessive expression of
cell adhesion molecules, chemokines, and increased
numbers of macrophages in human atherosclerotic
lesions. Labarrere, Nelson, and Faulk16 detected that
Fig 2. Correlation between TGF-β staining score and the
presence of CAV after transplantation.
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early activation of coronary endothelial lining in the
transplanted heart predicts the development of CAV.
Other studies17 have shown infiltration of macrophages
in chronic liver and renal allograft rejection. Conse-
quent activation of endothelial and smooth muscle cells
with subsequent expression of leukocyte activation
molecules and increased secretion of adhesion mole-
cules (P-selectin and intercellular adhesion mole-
cule–1) may contribute to the development of CAV.18
These probably lead to endothelial surface changes pre-
viously identified as early events in the pathogenesis of
acute transplant rejection and the subsequent develop-
ment of CAV. With time, progressive myocardial fibro-
sis results and adventitial fibrosis of the subepicardial
tissues probably inhibits dilatation and remodeling of
the epicardial arteries by constriction.19
The role of TGF-β. TGF-β modulates a number of
crucial events potentially central to the genesis and
maintenance of CAV. These include macrophage
chemotaxis, suppression of lymphocyte function,
fibroblast chemotaxis, and proliferation, in addition to
the modulation of collagen synthesis.20,21 TGF-β is also
a strong stimulator of extracellular matrix synthesis.22
Many different cells can synthesize and release TGF-β,
including activated macrophages, lymphocytes, and
platelets23,24 (cell types recruited intensely to sites of
vascular injury in the development of the athero-
sclerotic process).22 Previous reports have confirmed
increased expression of TGF-β in vascular stenotic
lesions. In addition to its stimulating effect on cellular
and vascular smooth muscle proliferation, TGF-β is
also a strong stimulant of the secretion of endothelin, a
potent arterial vasoconstrictor.25 In renal allograft
recipients, TGF-β has been shown to strongly correlate
with the development of glomerulosclerosis.7
Gayle and associates26 assessed CAV on the basis of
an evaluation of ischemic changes in the endomyocar-
dial biopsy specimen. They concluded that ischemic
myocardial changes in the biopsy specimen were high-
ly specific for CAV (98%), with a positive and negative
predictive value for ischemic injury of 92% and 51%,
respectively. Their study also reported a low sensitivity
for the presence of disease. An association between
allograft rejection, the subsequent development of
CAV, and rejection episodes (especially those that are
mild and untreated) has been reported.27,28 
Current study. In the present study we have evaluat-
ed the risk factors for the development of CAV in car-
diac allograft recipients at our center. We have demon-
strated the significance of cardiac allograft cytokine
expression and an association with the subsequent
development of CAV. Recipients homozygous for high
TGF-β producer genotype were most likely to have
high TGF-β tissue expression. The level of TGF-β
expression in the endomyocardial biopsy specimen was
the most potent predictor of disease. The number of
Table IV. Comparison of variables between recipients according to their coronary artery disease status
No/minimal/mild CAV Moderate/severe CAV
Variable CAV score ≤ 6 (n = 82 recipients) CAV score ≥ 7 (n = 90 recipients) P value
Recipient age (y) 43 ± 6.5 49 ± 9.6 .2
History of IHD 49 (54%) 72 (80%) .002
History of PVD 3 (3%) 4 (5%) .6
Recipient male sex 67 (82%) 74 (81%) .9
Diabetes before surgery 4 (4%) 3 (4%) .7
Cholesterol > 7 mmol/L 4 (4%) 5 (6%) .5
Donor age (y) 34 ± 6.2 43 ± 8.2 .02
< 45 y 71 (86%) 57 (63%) .1
> 45 y 11 (14%) 33 (37%) .05
Donor sex 46 (56%) 80 (88%) .004
SAH % of donors 46 (56%) 69 (76%) .005
Ischemic time (min) 196 ± 44 188 ± 21 .3
Bypass time (min) 261 ±31 252 ±36 .6
Rejection episodes grade ≥ 2 3.2 ± 1.2 6.0 ±1.8 .002
Obesity ≥ 20 BMI 2 (3%) 5 (6%) .2
TGF-β score 4.2 ± 0.9 10.3 ± 1.6 .0003
Average macrophages/biopsy 16 ± 8 39 ± 13 .002
Homozygous high TGF-β genotype 66 (80%) 85 (95%) .03
Average CyA trough level at 2 y 121 ± 26 163 ± 19 .04
Serum creatinine > 200 mmol/L 11 (13%) 8 (9%) .6
IHD, Ischemic heart disease; PVD, peripheral vascular disease; BMI, body mass index; SAH, subarachnoid hemorrhage; CyA, cyclosporine level.
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ISHLT rejection episodes of grade 2 or more correlat-
ed significantly with higher myocardial TGF-β deposi-
tion and the development of CAV.
These findings suggest that frequent cellular rejec-
tion episodes during the first 2 post-transplant years in
recipients genetically predisposed to higher TGF-β
production initiate a series of inflammatory and
immunologic responses characterized by overexpres-
sion of TGF-β. This culminates in endothelial injury,
coronary intimal thickening, and development of CAV.
In agreement with previous work,25,29 we also report a
greater risk of the development of CAV in recipients
with a history of ischemic heart disease and in those in
whom the allograft donor was male. The increased
incidence of CAV among recipients in whom the organ
donor died of subarachnoid bleeding may be attribut-
able to the fact that many of these donors are likely to
have had chronic systemic hypertension.
Study limitations. Our analysis was limited by the
fact that the study population was restricted to recipients
surviving for at least 2 years after transplantation and
had undergone coronary angiography. We were unable,
therefore, to provide information about the very early
development of fatal CAV. The rationale for this
approach was based on the requirement to avoid acute
allograft rejection, particularly given the poor reliabili-
ty of immunohistochemical staining during rejection
(170 recipients had one or more episode of rejection
during the first 2 years). However, in view of the rela-
tively young donor age (32 ± 9 years), the incidence of
donor CAV was likely to have been low in this popula-
tion. Another limitation of our study was the suboptimal
sensitivity of contrast coronary angiography for the
detection of early CAV. The accuracy of coronary
angiography for detection of nonepicardial coronary
lesions is doubtful, and previous reports have demon-
strated severe CAV at autopsy in transplant recipients
shortly after a reportedly normal angiogram.30,31
Conclusions
Despite these limitations, this study has highlighted
the potential role of TGF-β in the development of CAV
for a period of up to 10 years after transplantation. The
donor-related risk factors for CAV are also significant.
Future studies at our institution will include the use of
intracoronary vascular ultrasound in the detection of
changes in different layers of the coronary artery and
correlation with TGF-β staining score in all surviving
Fig 3. Correlation between TGF-β staining score and number
of rejection episodes of grade 2 or more during the first 2
years after transplantation. CAD, Coronary artery disease.
Fig 4. Correlation between TGF-β staining score at the study
end point and the number of rejection episodes of grade 2 or
more during the first 2 years after transplantation. CAD,
Coronary artery disease.
Table V. Multivariable analysis for risk factors for
development of CAV after transplantation
Variable Risk factor 95% CI P value
TGF-β staining score/unit 2.63 1.89-3.18 .0002
Homozygous TGF-β genotype 1.59 1.33-1.73 .001
Donor male sex 1.19 1.12-1.24 .02
Donor age > 45 y 1.33 1-2.3 .03
Rejection episode 1.95 1.62-2.31 .003
IHD before transplant 1.66 1.2-1.92 .03
Donor SAH 1.11 1.02-1.21 .04
IHD, Ischemic heart disease; SAH, subarachnoid hemorrhage.
recipients. Increased understanding of the etiology of
CAV and the role of cytokines in its development will
allow a clearer definition of the group of patients at high-
er risk. We suggest that the management of CAV in heart
transplant recipients can be considered in a stepwise
fashion. First, individuals identified by their risk factors
(Table V) should be monitored more closely. We suggest
that high-risk patients be targeted for intracoronary vas-
cular ultrasound even in the absence of angiographic evi-
dence of CAV. Second, modification of the biopsy regi-
men and immunosuppression may be important for
some patients, particularly those who are homozygous
for TGF-β1 gene. Third, a number of pharmacologic
agents (eg, statins, antihypertensives), as well as better
control of weight, diabetes, and hypertension, may have
the potential to minimize or slow the occurrence of CAV
in selected high-risk recipients. Finally, we suggest that
immunologic strategies to manipulate cytokine expres-
sion in cardiac allografts may improve the survival and
function of cardiac allografts. 
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Dr Leonard Bailey (Loma Linda, Calif). Dr Hutchinson, I
applaud your effort to shed some new and relevant light on
the still-perplexing issue of CAV. Your data suggest that 9
variables significantly separated the 102 recipients with triv-
ial or no CAV from the 70 recipients who had angiographi-
cally documented moderate to severe CAV. Seven of these 9
variables, including your newly devised TGF-β scoring sys-
tem, retained significance in multiple regression analysis as
independent risk factors for the development of coronary
artery disease. Two most significant risk factors in your study
were total number of rejection episodes and a TGF-β score
higher than 7. 
I have a couple of comments to make, not to mention the
insensitivity of routine angiography to identify significant
degrees of CAV. 
The first comment relates to the details of the TGF-β scor-
ing system. About half the points contributing to the score
seemed reasonably quantitative and hence objective in nature.
They include the number of macrophages and the percent
fibrosis in the biopsy specimens. The remainder of the scoring
system seems quite subjective, based on shades of staining or
presence of TGF-β. I have two questions relating to that. First,
were the histologic graders blinded to the study group data?
Dr Hutchinson. Yes, they were.
Dr Bailey. Second, your database included more than
12,000 myocardial biopsy specimens. How many were actu-
ally subjected to immunohistochemical analysis for the pur-
poses of this study?
Dr Hutchinson. About 3500.
Dr Bailey. About a fourth of them. That is a lot of work. 
My second comment relates to the role of TGF-β and solid
organ transplantation. TGF-β is a multifunctional protein
among a large family of cytokines that play a role in the
repair of vessel injuries. It is, of course, of enormous interest
to our interventional cardiology colleagues since their bal-
loons and stents seem to up-regulate cell growth and prolifer-
ative functions of this molecule. However, TGF-β is also a
powerful immunoregulator, and its immunosuppressive
behavior or function is currently under investigation as a
transgene in experimental studies. You have suggested
immunologic down-regulation of TGF-β as a strategy to
reduce CAV. Since TGF-β is so ubiquitous in recipient tissue
and its global effects on cell growth and differentiation are so
important to the health of the recipient, would it not be better
to leave it alone, simply as a marker of graft injury or in this
case as a possible prognostic indicator for the development of
coronary vascular disease? It occurred to me alternatively
that you could examine methods of up-regulating the
immunosuppressive functions of this molecule to enhance
graft survival. Could you comment on any of those issues?
Dr Hutchinson. TGF-β has many functions, including
suppression of lymphocyte proliferation. In the acute situa-
tion, a little bit of TGF is probably beneficial. However, in the
chronic situation in which TGF is up-regulated, chronic
rejection of the lung, kidney or liver is likely to develop in
patients who are genetically inclined to overproduction of
TGF. As an example, 38 of 39 individuals in whom 80%
restenosis developed are the high TGF-β genotype. That is
ample evidence that TGF is associated with the kind of lesion
that develops in the transplant. TGF is not the only factor
involved. We are currently investigating the genetics of vas-
cular endothelial growth factor, platelet-derived growth fac-
tor, α and β, basic fibroblast growth factor, and insulin-like
growth factor–1. All of those may play a role, but the pre-
dominant one appears to be TGF-β. In the chronic situation,
TGF-β appears to be playing a major role in the development
of disease. 
Dr Bailey. How do you suggest we in the transplant com-
munity use this information in the day-to-day surveillance of
our patients? 
Dr Hutchinson. I think you can look at biopsy specimens
very easily for staining for TGF, regardless of whether you
want to develop a very complex scoring system, as our
pathologists have. Our pathologists were blinded, and each
slide was read by at least two or three of them. They con-
ferred to agree on a score, and they used all sorts of controls
for the intensity of staining. Our pathologists exercised a
great deal of care, but TGF-β staining could be incorporated
into a routine pathologic system. 
You mentioned immunosuppression. We know that
cyclosporine increases TGF-β production both in vivo and in
vitro, and there is actually a very close correlation between
cyclosporine trough levels and circulating levels of TGF.
Also, at least in lung transplant recipients, there is an associ-
ation between the development of lung fibrosis and the
cyclosporine trough level. We might actually think about
switching our longer term patients from cyclosporine to
something less damaging. 
Dr Mark Pelletier (Montreal, Quebec, Canada). I have a
question about TGF-β, one of its roles being that of a proan-
giogenic factor. In these patients with severe CAV, might the
expression of TGF-β in fact be secondary to the heart’s need
to make new vessels, perhaps new collateral vessels? Would
TGF-β be increased in the same manner as vascular endothe-
lial growth factor or basic fibroblast growth factor? Have you
considered this possibility?
Dr Hutchinson. It appears to be the other way around,
because the genotype predicts the development of coronary
artery disease, rather than the other way around. However, I
think you are right about vascular endothelial growth factor,
and we are looking at the genotype associated with that.
